Loading
A phase 1 trial of MT-303 run by Myeloid Therapeutics, now recruiting.
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC is a phase 1 interventional study registered as NCT06478693 by Myeloid Therapeutics, with 70 participants planned, started 2024-07-01, primary completion expected 2027-12-31. Conditions recorded: Hepatocellular Carcinoma. Interventions recorded: MT-303, MT-303 +Atezolizumab + Bevacizumab.
Shares CREATE Medicines and the tag pipeline.
Shares CREATE Medicines and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/